{name}
{subtitle}
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
city
~36 mi. (Tulsa, Oklahoma, +523 more cities)
facility
Oklahoma Cancer Specialists and Research Institute-Tulsa
drug
cabozantinib, +2 more drugs
drug type
immunotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~36 mi. (Tulsa, Oklahoma, +159 more cities)
facility
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
city
~36 mi. (Tulsa, Oklahoma, +100 more cities)
facility
Oklahoma Cancer Specialist and Research Institution, LLC
condition
Fallopian Tube Adenocarcinoma, +14 more conditions
drug
carboplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
city
~36 mi. (Tulsa, Oklahoma, +822 more cities)
facility
Oklahoma Cancer Specialists and Research Institute-Tulsa
biomarker
ER Negative, +2 more biomarkers
drug
carboplatin, +3 more drugs
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
city
~36 mi. (Tulsa, Oklahoma, +556 more cities)
facility
Oklahoma Cancer Specialists and Research Institute-Tulsa
biomarker
CD19 Expression, +2 more biomarkers
drug
ibrutinib, +2 more drugs
drug type
chemotherapy, +2 more types